Inflammatory Bowel Diseases

Skip Navigation LinksHome > September 2013 - Volume 19 - Issue 10 > Consecutive Fecal Calprotectin Measurements to Predict Relap...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e31829b2a37
Original Clinical Articles

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Vos, Martine De MD, PhD1; Louis, Edouard J. MD, PhD2; Jahnsen, Jørgen MD, PhD3; Vandervoort, Jo G.P. MD4; Noman, Maja MD5; Dewit, Olivier MD, PhD6; D'Haens, Geert R. PMD, PhD7,8; Franchimont, Denis MD, PhD9; Baert, Filip J. MD10; Torp, Roald A. MD11; Henriksen, Magne MD, PhD12; Potvin, Philippe M.R. MD13; Van Hootegem, Philippe P. MD14; Hindryckx, Pieter M. MD, PhD1; Moreels, Tom G. MD, PhD15; Collard, Arnaud MD16; Karlsen, Lars Normann MD17; Kittang, Eirik MD, PhD18; Lambrecht, Guy MD19; Grimstad, Tore MD, PhD17; Koch, Jonas MD20; Lygren, Idar MD, PhD3; Coche, Jean-Claude R.J. MD21; Mana, Fazia MD, PhD22; Van Gossum, André MD, PhD9; Belaiche, Jacques MD, PhD2; Cool, Mike R. MD19; Fontaine, Fernand MD16; Maisin, Jean-Marc G. MD23; Muls, Vinciane MD24; Neuville, Bart MD28; Staessen, Dirk A. J. MD25; Van Assche, Gert A. MD, PhD5; de Lange, Thomas MD, PhD20; Solberg, Inger Camilla MD, PhD3; Vander Cruyssen, Bert J.K. MD, PhD26,27; Vermeire, Severine A.R.A. MD, PhD5

Collapse Box


Background: This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab maintenance therapy.

Methods: This prospective multicenter study enrolled adult patients with UC in clinical remission under infliximab maintenance therapy. Fecal calprotectin levels were measured every 4 weeks. Sigmoidoscopies were performed at inclusion and at study end. Relapse was defined as a clinical need for change in treatment or an endoscopic Mayo subscore of ≥2 at week 52. Sustained deep remission was defined as a partial Mayo score <3 at all points and an endoscopic Mayo score 0 at week 52.

Results: Full analysis was possible for 87 of 113 included patients with UC (77%). Of these patients, 30 (34.4%) were considered to be in sustained deep remission and 13 (14.9%) to have relapsed. Calprotectin levels in patients with sustained deep remission remained very low (median < 40 mg/kg at all time points). Patients who flared had significantly higher calprotectin levels (median > 300 mg/kg) already 3 months before the flare. Further receiver operator curve analysis suggested that a calprotectin level >300 mg/kg had a reasonable sensitivity (58.3%) and specificity (93.3%) to model flare. Two consecutive calprotectin measurements of >300 mg/kg with 1-month interval were identified as the best predictor of flare (61.5% sensitivity and 100% specificity).

Conclusions: Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.